All about health

NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended March 31, 2024. All amounts are in United States dollars unless otherwise...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a...

BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours. A presentation on the Company's first quarter 2024 results by...

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will be...

FMC Corporation , a leading global agricultural sciences company, today announced a research agreement with AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health. The agreement will accelerate...

IQVIA Holdings Inc. ("IQVIA") announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter...

Revance Therapeutics, Inc. , today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Financial Highlights In connection with the exit of the Fintech Platform business, the results of the...

Kite, a Gilead Company , and Arcellx, Inc. today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma...

Arcellx, Inc. and Kite, a Gilead Company , today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma...

Revance Therapeutics, Inc. , today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and...

CareDx, Inc. ? today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter revenue of $72.0 million. Revenue for Testing Services of $53.8 million, an increase of 15% as...

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate...

NovaBay® Pharmaceuticals, Inc. reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products...

OmniAb, Inc. today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. "The OmniAb team continued to make great progress this past quarter in advancing and expanding our...

Guardant Health, Inc. , a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $168.5 million for the first quarter of 2024, an increase of...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. "The IMPALA-2 trial remains on-track...

Nektar Therapeutics today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable...

Evolent Health, Inc. , a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with...

Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial...

The Princess Margaret Cancer Foundation is thrilled to unveil The Princess Margaret's Cricket to Conquer Cancer, North America's premier street cricket fundraiser. This groundbreaking initiative is slated to be the largest of its kind in the country....

Natural Grocers by Vitamin Cottage, Inc. today announced that the Company's Board of Directors has declared a quarterly cash dividend of $0.10 per common share. The dividend will be paid on June 19, 2024 to all stockholders of record at the close of...

Lantern Pharma Inc. , an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, today announced...

MEI Pharma, Inc. , a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0...

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of...

Evolent Health, Inc. , a company that...

Vapotherm, Inc. , ("Vapotherm" or the "Company"), today announced first quarter 2024 financial results and related highlights. First...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare...